Market Intelligence, Clinical Progress, and High-Purity Reagents for Exosome-Targeting & Lysosomal Delivery.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD63 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD63 (EC2 Loop) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View CD63 Products |
| Gene Delivery | CD63 Lentivirus Premade Particles Full-length ORF for stable cell lines. Essential for multi-pass transmembrane conformation preservation. |
View CD63 Products |
| Benchmark Ab | Anti-CD63 Recombinant Antibody Recombinant positive control for flow cytometry and Western Blot. |
View CD63 Products |
| Validator | CD63 siRNA Set For knockdown verification in functional assays. |
View CD63 Products |
| Related Target A | CD81 Tetraspanin family member; critical control for exosome specificity screening. |
View CD81 Products |
| Related Target B | CD9 Co-expressed exosomal marker; essential for profiling cross-reactivity. |
View CD9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Tetraspanin | Lentivirus-mediated stable cell line expression preserves native 4-transmembrane structure. |
| Glycosylation-dependent Epitope Mapping | HEK293 host expression ensures human-like post-translational modifications of the EC2 loop. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD63/LAMP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD63 therapeutics is intensifying, with major players shifting focus from traditional mAbs to exosome-based drug delivery systems and bispecific antibody conjugates. As first-generation therapies reach the clinic, the next wave of R&D is targeting CD63 as a fast-internalizing shuttle for lysosomal-targeting chimeras (LYTACs) and antibody-drug conjugates (ADCs) in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Exosome Therapeutics | Codiak BioSciences, Evox Therapeutics | Rare Diseases, Oncology | Exosome isolation and quantification (Need high-purity CD63 EC2 Loop) |
| LYTAC / Degrader | Lycia Therapeutics | Autoimmune, Solid Tumors | Lysosomal trafficking validation (Need Lentivirus for stable reporter lines) |
| ADC / Bispecific | Academic institutions, Biotech startups | Refractory Cancers | Internalization kinetics (Need sequence-verified benchmark antibodies) |